SHANGHAI, July 15, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive topline data results of the maintenance period from a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of subjects with moderately-to-severely active ulcerative colitis (UC). VELSIPITY® (etrasimod) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest's licensing partner, Pfizer. VELSIPITY® is the first and only advanced oral UC therapy approved for use in patients 16 years of age or older in the EU. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the New Drug Application (NDA) for VELSIPITY® in April of this year.
"These positive results are both clinically meaningful and statistically significant, which further demonstrate that etrasimod has the potential to be a breakthrough option for patients with moderately-to-severely active UC " said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "The number of UC patients in China is projected to double from 2019 to approximately one million by 2030, highlighting the urgent need for novel treatments. Etrasimod is expected to provide a new oral therapy option with a favorable benefit-risk profile for UC patients. Autoimmune disease is a key therapeutic focus for Everest. We plan to submit an NDA to China's National Medical Products Administration this year to benefit more Chinese patients as soon as possible."
The positive results are from a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod 2mg conducted in Asian countries. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. Patients with inadequate response or intolerance to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy were randomized to receive etrasimod 2mg once-daily or placebo for 12 weeks of induction treatment. Patients who had completed 12- week of induction treatment and responded to induction treatment were re-randomized into the 40-week maintenance period to receive 2mg once-daily etrasimod or placebo.
The primary efficacy endpoints for the induction period and maintenance period were the proportions of patients achieving clinical remission at Induction Week 12 and Maintenance Week 40, respectively. The key secondary endpoints of the study were the proportion of patients achieving endoscopic improvement and clinical response at Week 12 for the induction phase and at Week 40 for the maintenance phase. Safety was assessed throughout the study, with treatment-emergent adverse events (TEAEs) graded by the Common Terminology Criteria for Adverse Events (CTCAE).
The data of maintenance treatment confirmed that, after 40 weeks of treatment, etrasimod demonstrated significant clinical and statistical improvements over placebo in the primary and all key secondary endpoints (p<0.0001), and other secondary endpoints (including mucosal healing and endoscopic normalization, both p<0.0001). The safety profile of etrasimod was consistent with previous studies, with no new safety signals observed. Detailed results will be presented at upcoming academic conferences.
At the 12th Asian Organization for Crohn's and Colitis (AOCC 2024) held in Xi'an from June 14 to 16 this year, detailed data from the 12-week induction phase of the Phase III clinical study of etrasimod in Chinese patients were announced. A total of 320 subjects from China were randomly assigned to receive induction treatment with etrasimod 2mg or placebo. The results showed that the clinical remission rate for patients treated with etrasimod 2mg was 24.5%, compared to 5.8% for those treated with placebo (difference 19.7%, p<0.0001). Compared to the placebo group, patients treated with etrasimod demonstrated significant clinical and statistically significant improvements in all key secondary endpoints. The endoscopic improvement rate was 37.0% for the etrasimod group and 10.7% for the placebo group (difference 28.0%, p<0.0001); the clinical response rate was 57.4% for the etrasimod group and 28.2% for the placebo group (difference 30.6%, p<0.0001). The safety results for Chinese patients were consistent with previous studies, with no new safety signals observed.
About VELSIPITY® (etrasimod)
VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK and Macau, China for VELSIPITY® in ulcerative colitis.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.
Forward-Looking Statements:
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
source: Everest Medicines
【你點睇】港府本年度已錄逾2千億元赤字，有議員指或難符基本法力求收支平衡之規定。你認為當局應如何解決財政問題？► 立即投票
